N/A
N=36
Macrophage Markers in Periodontal and Peri-implant Health and Disease
Peri-Implantitis · Periodontitis
Bottom Line
View on ClinicalTrials.gov: NCT05242354 ↗Enrolled (actual)
36
Serious AEs
0.0%
Results posted
May 2023
Primary outcome: Primary: CD80 — 7340.34; 10854.71; 6448.43; 9874.8 arbitrary density units
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Biruni University
- Primary completion
- Dec 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY CD80 |
7340.34; 10854.71; 6448.43; 9874.8 | — |
| PRIMARY CD163 |
24092.85; 36419.24; 2167.97; 6272.90 | — |
| PRIMARY CD206 |
17648.07; 15063.13; 4049.07; 16862.31 | — |
| PRIMARY CD80/CD163 Ratio |
0.417; 0.413; 3.075; 0.801 | — |
| PRIMARY CD80/CD206 Ratio |
0.376; 0.525; 1.366; 0.405 | — |
| SECONDARY Probing Depth |
1.5; 7.78; 7.78 | — |
Summary
Macrophage surface markers (CD80, CD163 and CD206) will be evaluated in periodontally healthy gingiva, healthy peri-implant mucosa, and periodontitis and peri-implantitis lesions.
Eligibility Criteria
Inclusion Criteria
- diagnosed with generalized Grade C Stage III periodontitis
- diagnosed with peri-implantitis
- periodontally healthy individuals with dental implants in the primary healing period
- periodontally healthy individuals who are in need of crown lengthening / gingivectomy or extraction
Exclusion Criteria
- systemic disease
- smoking / former smokers
- regular medicine intake
- antibiotic or anti-inflammatory medicine intake in the last 3 months
- pregnancy or lactation
Data sourced from ClinicalTrials.gov (NCT05242354). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.